Compare MGNX & BLZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNX | BLZE |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 218.8M |
| IPO Year | 2013 | 2021 |
| Metric | MGNX | BLZE |
|---|---|---|
| Price | $3.15 | $7.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.00 | ★ $7.60 |
| AVG Volume (30 Days) | ★ 715.2K | 459.7K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,500,000.00 | $145,835,000.00 |
| Revenue This Year | N/A | $10.16 |
| Revenue Next Year | $3.19 | $10.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.27 |
| 52 Week Low | $1.19 | $3.26 |
| 52 Week High | $3.88 | $10.86 |
| Indicator | MGNX | BLZE |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 91.56 |
| Support Level | $1.45 | $7.35 |
| Resistance Level | $3.26 | $8.16 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | -0.05 | 0.25 |
| Stochastic Oscillator | 33.55 | 82.08 |
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.